Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial.

@article{Henry2012EfficacyAS,
  title={Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial.},
  author={Robert R. Henry and S. A. Jegaraya Mudaliar and Linda Kanitra and Michael Woloschak and Raffaella Balena},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2012},
  volume={97 7},
  pages={2370-9}
}
OBJECTIVE This study assessed the efficacy and safety of once-weekly taspoglutide in patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone compared with placebo. DESIGN In this randomized, double-blind, parallel-group, placebo-controlled trial (T-emerge 3), 326 patients were randomized to once-weekly sc injections of taspoglutide 10 mg, taspoglutide 20 mg (10 mg for first 4 wk), or placebo. The primary endpoint was change from baseline in glycosylated… CONTINUE READING